After nearly eight years, Yumanity’s time as an independent company appears close to an end.
The biotech was established in late 2014 — the creation of Tony Coles, Susan Lindquist and Ken Rhodes, each well-known in the pharmaceutical industry for their respective expertise in corporate management, protein research and brain drug development. Yumanity sought to better understand neurodegenerative diseases and find potential treatments for them using an unorthodox tool: yeast.
